SOX2 as prognostic factor in head and neck cancer: a systematic review and meta-analysis. (November 2014)

• Record Type: Journal Article
• Authors: Li, Weimin; Li, Baoping; Wang, Rongguang; Huang, Dongyan; Jin, Wei; Yang, Shiming
• Is Part Of: Acta oto-laryngologica. Volume 134:Number 11(2014)
• Page Start: 1101
• Page End: 1108
• Publication Date: 2014-11
• Subjects: Otolaryngology -- Periodicals; Ear -- Diseases -- Periodicals; Throat -- Diseases -- Periodicals; Otolaryngology -- Electronic Resources; Otorhinolaryngologic Diseases; 617.8
• DOI: 10.3109/00016489.2014.913311
• Languages: English
• ISSNs: 0001-6489

Abstract

<abstract> <title>Abstract</title> <p> <italic>Conclusion:</italic> SOX2-positive head and neck cancer patients had a worse prognosis, and this was associated with common clinicopathological poor prognostic factors. <italic>Objective:</italic> To investigate the correlation between SOX2-positive head and neck cancer and clinicopathological features and its impact on survival. <italic>Methods:</italic> A search in PubMed and Chinese CNKI (up to 1 July 2013) was performed. Only articles in which SOX2 antigen was detected in situ localization by immunohistochemical staining were included. This meta-analysis was done using RevMan 5.2 software. Outcomes included overall survival and various clinicopathological features. <italic>Results:</italic> A total of 926 gastric cancer patients from 9 studies were included. Meta-analysis showed that patients with SOX2 expression had a significantly worse 5-year overall survival compared with those with low expression (relative risk (RR) = 2.38, 95% confidence interval (CI) = 1.10–5.15, <italic>p</italic> = 0.03, random-effect). With respect to clinicopathological features, SOX2 overexpression as assessed by the immunohistochemistry method was closely correlated with tumor T stage, lymph node metastasis, and TNM stage.</p> </abstract>